pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-605 |
Genomic Coordinates | chr10: 51299573 - 51299655 |
Synonyms | MIRN605, hsa-mir-605, MIR605 |
Description | Homo sapiens miR-605 stem-loop |
Comment | None |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | |||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-605-5p | ||||||||||||||||||||||||||||||||||||
Sequence | 16| UAAAUCCCAUGGUGCCUUCUCCU |38 | ||||||||||||||||||||||||||||||||||||
Evidence | Experimental | ||||||||||||||||||||||||||||||||||||
Experiments | SAGE | ||||||||||||||||||||||||||||||||||||
Editing Events in miRNAs |
|
||||||||||||||||||||||||||||||||||||
SNPs in miRNA |
|
||||||||||||||||||||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | ZNF507 | ||||||||||||||||||||
Synonyms | - | ||||||||||||||||||||
Description | zinc finger protein 507 | ||||||||||||||||||||
Transcript | NM_001136156 | ||||||||||||||||||||
Other Transcripts | NM_014910 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on ZNF507 | |||||||||||||||||||||
3'UTR of ZNF507 (miRNA target sites are highlighted) |
>ZNF507|NM_001136156|3'UTR 1 GTGGAATAATGACTCGAGCAGGAAAGCAGTAGAAGAGGATTCCTTCACCACAGTTTCACCTTTACGCTGTCAGACAACTT 81 CCTGCCACAGAAGAAGTCGTTGATGTGATTTTTGAGGAAATGACAGATGTGACTTTGGAACCAAACTTGTAATAAAAGGA 161 ATTCCAAATGGACAAGCAGTAATGATATTTAAATATTTTGAGTGAGGGGGAGTGGGTCAAAGAGGAAGTAGAGGTGTAAT 241 CCTGTATTAACCCTCTGTCACCCCTTCTTAGTGTCGAGTGTATTTATTAATAAAAGCTTATTAGAGTGTAGAAATGCCAG 321 CAAGAGTTAAGAAAGGGCTTTTCAGGAACTATTCTAAAAGTCATAAAAGGGTCACAGTCTTAAGCAGAGCTTAGTTTTCT 401 TCTCACTTGTCAAATGCAGACTGTGAGGCCTCCAGTGAGAAATGGGAGGCAGTTCTGGGAGGGGGTTTTTTCAGTGTCAC 481 CAACAGAGTCAACAAGGAAACATAATTAGAGGGCTTTGAAATGATCTACTGAAATACCTAAATTGATAGAAATTAATCAT 561 ACTCAATCTAGGACATGTTCCTTTACTCCTTAAAAAAGAAAGGAAAGATCTCTAAATTCAAAGCTAGATTGTAAATAGGC 641 ATTCAAGAAGTATTGTCTTAAATTTACGATGAATTTCTTGTGAGCAGAGGACGAAACAGGTGAATTCTCACCAGACTCAA 721 ACCAGATCTCAATTCGTAGTAATGCTAAATCGTCTTCCGTGTTCTCAGAGGTTCTTTTCAGTGTCTGTCAGAACTTGGCA 801 TACTTTCTCCATAGTACGTAGACCTTCTAATACTCTGCTAAATGAAACCACACTTGTTATCTGAAAGTGTGTGAAAGAAA 881 CAATGTATGAAAATTTACATTTGATCATCCGGCATTGGAAATAGTTTGAACTATTTCCAAAAATCCCTTAGGGGATGAGG 961 GGTGAAATTTAAAAGCTCCTGAAAATGAGTACTGCTGTGTTGAGCTTTTCTTTCCTGGGGTATATTAATTTAGTTATATT 1041 TAGCAGAAGAGGAATATAACCAAATGTGACTAAAATATAGCAGAAATTCAGGTTGTTTGTAAAAATTTTAATAACAAATA 1121 GCATTTGGCAAGTCTATAGGATTCTTCCTATCTGGAAATTCTATTTTGTTAGAGTGCGATAGGACATATGGAAAACCAAC 1201 ACAAAGTGCTTTAGCATTAAAACTCACCATCAAATAGATGTAATCTTATTAATTACACATTTTGTATTTTAATTATTTCA 1281 AGGAGTGAAGAAAACAGGGTGTTTTTGTTTTTGTAGTTCTGATTACTCATTTATGCATTGTTTTGTTTAAGTAAATTCTG 1361 CCTACAAGTGAAAAGGTCGGTGCGCTCTTCTGTGCACCATCCTCACGGTGCTATTTCCGAATATCTGAATATTGATTTCT 1441 AACACCTGGATGAGGCTGTGACCGATCAACTTGGAACACTGTAAAGGTTTTCGAATGGGATACGCTGTAGGCACGTTTTA 1521 AGAAGTATTCTGTTCCTAAAGTCCAGGTATGATTGGATTAATATTTATAAAATTATTATTAGGAATTATTTAAGTGGGGC 1601 CAGGCATCTTGCAACATTTTCTGATTTTTTTTTCTTTCTTTCTAATCTCATTTTGGTGATATTTAAACAAACATAAATGA 1681 TTGTAACTTTGCAGCTTTTTTATTTAGGTAGCTTTAATTTATTTATGAAAGTTAATCCATTTCTGATACGTGGTTTTTAA 1761 AAATATGAAATGGATTTATATATACTATATTCCTCAAATCCACTGTATGTGGACTTATATTCATTTTCTCCTTTTTTCGG 1841 AATTGAAACATTTTAATTTCAAATTCAAATAGAACATTTAAAATGATTTCATTATTATTACCCATACTGTTGCCACTCAT 1921 ATTGTAAGTCAGTTTTTTCATTGCTGGTACAATGACTCAGTATTTCTTTATAAAAATCTGTTGTTCTGAAAATCAACAAC 2001 CTTAGAAGGATTTTGTCTTAGAAAATTTCCTTGGCTTTAGTTTTATATCATATTTAGAAAATAATAATGAAAAGCATCCC 2081 CAAAATTTCAATGATGTGAATTTTTAAATTACCTTTATTTCTTTAAACTAATTCCATTGATTGTTACTTAAATTTTCCAC 2161 CTGGAATCATGGATTTAAAATTTCCCCACCTCATGGGGAAAAAACTAACCCAGAAGTTCAAAGCCTTTAAAGTTTCATCT 2241 GATTCTGGCCTTAGAATTGTCCTTAAAAGCTTTCTCCTGGCCGATAGGAGGAAGCATATATCAAGGAGGTTCTTTCCCTT 2321 CCCATTATCATTTTGTGGCAAGCCTTAAGTTAACAATGTGTCTACCAAGAACAATTGAGTTTTCTAAAAGTAATAATGAA 2401 GATTATGCAATTCTAACTGTAGAAGAGATAGCTATTAAAATAATCAGTAGCCTGGGCATAGTGGCTCACACCTGTAATCC 2481 CAATACTTTAGAAGGCCAAGGCTGGAGGACTGCTTGAGTCCAGAAGTTTAAGACCAGCCTGGGCAACACGGGGAGACCCT 2561 GTCTCTACAAGAAATTAAAAATTAGCCAGGCATAGTTGGCACGTGCCTGTAGCACCAGCTACTTGGGAGGTTAAGGTGGG 2641 AGGATCACTTGAGCCTGGGAGATAGAGGCTTGCAGTGAGCCGTGATGGCACCATTGCACTCCAACCGGGGTGACAGATGA 2721 GGTCCTCTGTTTACCTCCCCCCCCAAAAAAAAAATTCAGTAGGAATTCCTTCATAGAATAACATGTTATTTATTGGTATT 2801 GACTTCTTATTAGACAGAGCTCATAGTATTTGTTTTCTGCTCCGAACACTTAAAAAATACTAAGACGTGATAGTGAAAAT 2881 AGCTTTGAAAAGAAACTACATATGGCAAAGGTGGGGAGGGGGGAAGATGATGCATTCTGATCATTATAAAGAATACTTTT 2961 CAGGGCTCTATCATTTTCTCCCTTTCTCTAATCATCCAGAATATGGCGGGTGTCCCAGTGTTCAACAGTATCATGCTAAT 3041 ATTCCATTTGATCGGTAGTCCAAGTTCTTTGGCCAGATAGTGCAATGTTGTGACACCGACCGAAGCCTTTGTTCTGGATC 3121 TTTCTTCCTATTGAAGGTGGCTGCTGGTGGCTTCATAATTTTCTGTTTTTTTTCTCACAAAGTAAATGGTGGGCATCCAT 3201 GTTTACATTGCACCTTCCCGTGCTGTAATTGGCTTGACAAAGACAAGCAGGCTTCTCTGTTGAGACTTATTGTGTTTTTA 3281 GTTTTCATAGACACTTATTTAATCTTTTTAAATTGTACAGCAAGGTGCTCTAAGTAATATTCGATAAAATATATTTAATA 3361 GAAATTTGCGTTTGATATTCATGAACATGAATACATGTATTTTTTTAAGAAATAAGTATTGTGTAACACTATGGCATTGC 3441 TTCTATAGCCAAAGTATAAAAATTTCTGGAATACTGACATGTAAAGACTACAGTTAATTCTGACACTGTATCTTATTAAA 3521 ATAGGATGATTTGCATTTTGTAAAATTATCCTGCACATCAAGCTGCATGCCTTAAAGCGGAAACTCTAGGACTGTGTTCA 3601 TGGGAGAGCAGTTCATCTGTTCAGAACAGTGAGGCAAGGTCTGTAGTGCTTCTTTAACTACCTTTGGAAATACTGTACAA 3681 TGTTAGAATAATTTATTTTGCTTTACAGGAGTTTGTCATGTATTGACTTTAATATTGTATTTTGGTAATAAATTTTTTGT 3761 TAAAAAAAACTTGGCTCCAAGTTCTATTAACCACAGGTTGTGTTCATTCTTTTCCTGGAAATGATGACTTTATTGCTTAG 3841 AAAGTTGTAAATAATTAAAAGCTTCCCAAGAGTTAAATGAAGGTTATGATGACTCTTGATAACTTGTTAATCTGTTGCTG 3921 ACTAGCATTAGACTGTTACACGAAGATAAACTGAATAAGCATTTAGCTTTTTAAATCATTTTAAAAATTAAGTCTAATTT 4001 TGAAGCTTTTTTCCTTGCTACCCAGTTCAGTTTCTCTTCCAAATGTGACACGCTTATATGCTTTCAATTCTGATATAGTC 4081 AAAGTGCTAAAGACTAGTTCTGCTATTGACGAAGGAATTAGCATTCCTTAGTGAAGGCCAAAAACTACAGTGATATGTTC 4161 ACACCTTGATCACTCTGTCGTCTATACAGACAGCTATTGACATATTTGTTGCATTGACGAAGCTAACATCATCTGACTGT 4241 ATCGTGGGTCTGGTTATCCATTTGTGCCCTAGAATCCTGGGTCACCTCAGTTGAAAGTGACCAAGGCCAAATATTTCGTC 4321 CCATGCTTCCCAGGGACAACATAATCATATCCCCTGTCTTTGAAAAACCCAATCTGAAACTGTGTCACTAACCTCCAAAT 4401 TAAAGAATCCGAGCATGGAAGCTCTAGAACGTATGGTCCAGTGTGGCAGCCACTATAATATCTAAGTGTAAAATACATAG 4481 CAGTTGCAAAGACTTAGTACAAAAAGAATGGAAATGTATTAACAGTTTTTTATATTGATTACATGTTGAAATGATATTTT 4561 GGTTTAAATAAAATATTAAAATTAAAAAAAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | TZM-bl |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM1462574. RNA binding protein: AGO2. Condition:TZM-bl ami BaL
... - Whisnant AW; Bogerd HP; Flores O; Ho P; et al., 2013, mBio. |
Article |
- Whisnant AW; Bogerd HP; Flores O; Ho P; et al. - mBio, 2013
UNLABELLED: The question of how HIV-1 interfaces with cellular microRNA (miRNA) biogenesis and effector mechanisms has been highly controversial. Here, we first used deep sequencing of small RNAs present in two different infected cell lines (TZM-bl and C8166) and two types of primary human cells (CD4(+) peripheral blood mononuclear cells [PBMCs] and macrophages) to unequivocally demonstrate that HIV-1 does not encode any viral miRNAs. Perhaps surprisingly, we also observed that infection of T cells by HIV-1 has only a modest effect on the expression of cellular miRNAs at early times after infection. Comprehensive analysis of miRNA binding to the HIV-1 genome using the photoactivatable ribonucleoside-induced cross-linking and immunoprecipitation (PAR-CLIP) technique revealed several binding sites for cellular miRNAs, a subset of which were shown to be capable of mediating miRNA-mediated repression of gene expression. However, the main finding from this analysis is that HIV-1 transcripts are largely refractory to miRNA binding, most probably due to extensive viral RNA secondary structure. Together, these data demonstrate that HIV-1 neither encodes viral miRNAs nor strongly influences cellular miRNA expression, at least early after infection, and imply that HIV-1 transcripts have evolved to avoid inhibition by preexisting cellular miRNAs by adopting extensive RNA secondary structures that occlude most potential miRNA binding sites. IMPORTANCE: MicroRNAs (miRNAs) are a ubiquitous class of small regulatory RNAs that serve as posttranscriptional regulators of gene expression. Previous work has suggested that HIV-1 might subvert the function of the cellular miRNA machinery by expressing viral miRNAs or by dramatically altering the level of cellular miRNA expression. Using very sensitive approaches, we now demonstrate that neither of these ideas is in fact correct. Moreover, HIV-1 transcripts appear to largely avoid regulation by cellular miRNAs by adopting an extensive RNA secondary structure that occludes the ability of cellular miRNAs to interact with viral mRNAs. Together, these data suggest that HIV-1, rather than seeking to control miRNA function in infected cells, has instead evolved a mechanism to become largely invisible to cellular miRNA effector mechanisms.
LinkOut: [PMID: 23592263]
|
CLIP-seq Support 1 for dataset GSM1462574 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | TZM-bl / TZM-bl ami BaL |
Location of target site | ENST00000311921.4 | 3UTR | AUUUAUAUAUACUAUAUUCCUCAAAUCCACUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23592263 / GSE59944 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||
---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
107 hsa-miR-605-5p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT001230 | SEC24D | SEC24 homolog D, COPII coat complex component | 3 | 1 | ||||||||
MIRT016155 | TP53 | tumor protein p53 | 2 | 1 | ||||||||
MIRT016156 | TCEAL1 | transcription elongation factor A like 1 | 1 | 1 | ||||||||
MIRT016157 | MDM2 | MDM2 proto-oncogene | 2 | 1 | ||||||||
MIRT040476 | YBX1 | Y-box binding protein 1 | 1 | 1 | ||||||||
MIRT040477 | TMEM64 | transmembrane protein 64 | 1 | 1 | ||||||||
MIRT040478 | KDM5C | lysine demethylase 5C | 1 | 1 | ||||||||
MIRT040479 | TRAF4 | TNF receptor associated factor 4 | 1 | 1 | ||||||||
MIRT040480 | DRG1 | developmentally regulated GTP binding protein 1 | 1 | 1 | ||||||||
MIRT040481 | BCL9 | B-cell CLL/lymphoma 9 | 1 | 1 | ||||||||
MIRT055125 | SCD | stearoyl-CoA desaturase | 2 | 2 | ||||||||
MIRT057521 | CEP55 | centrosomal protein 55 | 2 | 2 | ||||||||
MIRT081129 | LDLR | low density lipoprotein receptor | 2 | 6 | ||||||||
MIRT096817 | ZSWIM6 | zinc finger SWIM-type containing 6 | 2 | 4 | ||||||||
MIRT100961 | CENPQ | centromere protein Q | 2 | 4 | ||||||||
MIRT263338 | ANAPC16 | anaphase promoting complex subunit 16 | 2 | 2 | ||||||||
MIRT274710 | CPSF6 | cleavage and polyadenylation specific factor 6 | 2 | 2 | ||||||||
MIRT311193 | ANKRD33B | ankyrin repeat domain 33B | 2 | 2 | ||||||||
MIRT360127 | DEK | DEK proto-oncogene | 2 | 2 | ||||||||
MIRT438269 | PSMD10 | proteasome 26S subunit, non-ATPase 10 | 2 | 1 | ||||||||
MIRT442464 | SLC25A13 | solute carrier family 25 member 13 | 2 | 2 | ||||||||
MIRT446110 | TSC22D2 | TSC22 domain family member 2 | 2 | 2 | ||||||||
MIRT463119 | ZNF507 | zinc finger protein 507 | 2 | 2 | ||||||||
MIRT470566 | POU2F1 | POU class 2 homeobox 1 | 2 | 2 | ||||||||
MIRT475059 | IVNS1ABP | influenza virus NS1A binding protein | 2 | 6 | ||||||||
MIRT482538 | ACTB | actin beta | 2 | 4 | ||||||||
MIRT494136 | DCAF7 | DDB1 and CUL4 associated factor 7 | 2 | 6 | ||||||||
MIRT495209 | EDN3 | endothelin 3 | 2 | 2 | ||||||||
MIRT495235 | LONRF3 | LON peptidase N-terminal domain and ring finger 3 | 2 | 2 | ||||||||
MIRT496762 | MANBAL | mannosidase beta like | 2 | 2 | ||||||||
MIRT498885 | ZNF12 | zinc finger protein 12 | 2 | 10 | ||||||||
MIRT499280 | NBPF11 | NBPF member 11 | 2 | 2 | ||||||||
MIRT507063 | H3F3B | H3 histone family member 3B | 2 | 2 | ||||||||
MIRT508352 | HES7 | hes family bHLH transcription factor 7 | 2 | 8 | ||||||||
MIRT510740 | SMC1A | structural maintenance of chromosomes 1A | 2 | 6 | ||||||||
MIRT519872 | ZFP62 | ZFP62 zinc finger protein | 2 | 4 | ||||||||
MIRT521272 | RTN4 | reticulon 4 | 2 | 4 | ||||||||
MIRT522324 | NFIB | nuclear factor I B | 2 | 6 | ||||||||
MIRT525011 | ACTN4 | actinin alpha 4 | 2 | 6 | ||||||||
MIRT526608 | AASDH | aminoadipate-semialdehyde dehydrogenase | 2 | 4 | ||||||||
MIRT529043 | ARL9 | ADP ribosylation factor like GTPase 9 | 2 | 2 | ||||||||
MIRT529545 | ZNF678 | zinc finger protein 678 | 2 | 2 | ||||||||
MIRT532500 | HOXA13 | homeobox A13 | 2 | 2 | ||||||||
MIRT532599 | SIX4 | SIX homeobox 4 | 2 | 2 | ||||||||
MIRT534044 | STK4 | serine/threonine kinase 4 | 2 | 2 | ||||||||
MIRT534087 | SPPL3 | signal peptide peptidase like 3 | 2 | 2 | ||||||||
MIRT534249 | SLC16A1 | solute carrier family 16 member 1 | 2 | 2 | ||||||||
MIRT534286 | SLC12A7 | solute carrier family 12 member 7 | 2 | 2 | ||||||||
MIRT534555 | RUNX1 | runt related transcription factor 1 | 2 | 2 | ||||||||
MIRT536765 | HOXB2 | homeobox B2 | 2 | 2 | ||||||||
MIRT537227 | GAN | gigaxonin | 2 | 2 | ||||||||
MIRT551105 | TTC8 | tetratricopeptide repeat domain 8 | 2 | 2 | ||||||||
MIRT552247 | DUSP3 | dual specificity phosphatase 3 | 2 | 2 | ||||||||
MIRT554361 | SFXN5 | sideroflexin 5 | 2 | 2 | ||||||||
MIRT557402 | H3F3C | H3 histone family member 3C | 2 | 2 | ||||||||
MIRT559116 | C16orf52 | chromosome 16 open reading frame 52 | 2 | 2 | ||||||||
MIRT560494 | BUB3 | BUB3, mitotic checkpoint protein | 2 | 2 | ||||||||
MIRT562296 | GLO1 | glyoxalase I | 2 | 2 | ||||||||
MIRT562597 | CAPZA2 | capping actin protein of muscle Z-line alpha subunit 2 | 2 | 2 | ||||||||
MIRT563857 | ALYREF | Aly/REF export factor | 2 | 4 | ||||||||
MIRT565665 | SIX1 | SIX homeobox 1 | 2 | 2 | ||||||||
MIRT568253 | BTF3L4 | basic transcription factor 3 like 4 | 2 | 2 | ||||||||
MIRT609593 | GPM6B | glycoprotein M6B | 2 | 2 | ||||||||
MIRT611552 | GGT6 | gamma-glutamyltransferase 6 | 2 | 2 | ||||||||
MIRT613451 | CYLD | CYLD lysine 63 deubiquitinase | 2 | 2 | ||||||||
MIRT615516 | PRRC2A | proline rich coiled-coil 2A | 2 | 2 | ||||||||
MIRT617766 | C17orf105 | chromosome 17 open reading frame 105 | 2 | 2 | ||||||||
MIRT619134 | MCOLN3 | mucolipin 3 | 2 | 2 | ||||||||
MIRT621365 | CAP2 | cyclase associated actin cytoskeleton regulatory protein 2 | 2 | 2 | ||||||||
MIRT625804 | MDC1 | mediator of DNA damage checkpoint 1 | 2 | 2 | ||||||||
MIRT626954 | PRDM2 | PR/SET domain 2 | 2 | 2 | ||||||||
MIRT627716 | RCAN1 | regulator of calcineurin 1 | 2 | 2 | ||||||||
MIRT628069 | KCNJ13 | potassium voltage-gated channel subfamily J member 13 | 2 | 2 | ||||||||
MIRT630451 | GTPBP8 | GTP binding protein 8 (putative) | 2 | 2 | ||||||||
MIRT635533 | ELMOD2 | ELMO domain containing 2 | 2 | 2 | ||||||||
MIRT636206 | SULF2 | sulfatase 2 | 2 | 2 | ||||||||
MIRT638763 | EPHA4 | EPH receptor A4 | 2 | 2 | ||||||||
MIRT640324 | STAT1 | signal transducer and activator of transcription 1 | 2 | 2 | ||||||||
MIRT644548 | SPOP | speckle type BTB/POZ protein | 2 | 2 | ||||||||
MIRT645114 | TMX2 | thioredoxin related transmembrane protein 2 | 2 | 2 | ||||||||
MIRT647778 | NANOS1 | nanos C2HC-type zinc finger 1 | 2 | 2 | ||||||||
MIRT650112 | ZCCHC9 | zinc finger CCHC-type containing 9 | 2 | 2 | ||||||||
MIRT650136 | ABCB7 | ATP binding cassette subfamily B member 7 | 2 | 2 | ||||||||
MIRT650310 | SLC35E2 | solute carrier family 35 member E2 | 2 | 2 | ||||||||
MIRT650930 | ST6GALNAC1 | ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 1 | 2 | 2 | ||||||||
MIRT651018 | ZNF740 | zinc finger protein 740 | 2 | 2 | ||||||||
MIRT653541 | SLC38A9 | solute carrier family 38 member 9 | 2 | 2 | ||||||||
MIRT655752 | NR2C2 | nuclear receptor subfamily 2 group C member 2 | 2 | 2 | ||||||||
MIRT656908 | KIAA1958 | KIAA1958 | 2 | 2 | ||||||||
MIRT657854 | GJD3 | gap junction protein delta 3 | 2 | 2 | ||||||||
MIRT658215 | FBXO21 | F-box protein 21 | 2 | 2 | ||||||||
MIRT659884 | CAPN7 | calpain 7 | 2 | 2 | ||||||||
MIRT659922 | CACNA1E | calcium voltage-gated channel subunit alpha1 E | 2 | 2 | ||||||||
MIRT660055 | C12orf5 | TP53 induced glycolysis regulatory phosphatase | 1 | 1 | ||||||||
MIRT664616 | LIMD1 | LIM domains containing 1 | 2 | 2 | ||||||||
MIRT665392 | WEE1 | WEE1 G2 checkpoint kinase | 2 | 2 | ||||||||
MIRT667887 | IP6K1 | inositol hexakisphosphate kinase 1 | 2 | 2 | ||||||||
MIRT669018 | CHORDC1 | cysteine and histidine rich domain containing 1 | 2 | 2 | ||||||||
MIRT688419 | DUSP2 | dual specificity phosphatase 2 | 2 | 2 | ||||||||
MIRT691888 | GXYLT2 | glucoside xylosyltransferase 2 | 2 | 2 | ||||||||
MIRT709530 | GEN1 | GEN1, Holliday junction 5' flap endonuclease | 2 | 2 | ||||||||
MIRT711013 | ABCD2 | ATP binding cassette subfamily D member 2 | 2 | 2 | ||||||||
MIRT714731 | CENPH | centromere protein H | 2 | 2 | ||||||||
MIRT719897 | PTGIS | prostaglandin I2 synthase | 2 | 2 | ||||||||
MIRT725028 | CX3CL1 | C-X3-C motif chemokine ligand 1 | 2 | 2 | ||||||||
MIRT734348 | P2RY12 | purinergic receptor P2Y12 | 3 | 0 | ||||||||
MIRT736719 | TNFAIP3 | TNF alpha induced protein 3 | 3 | 0 |
miRNA-Drug Associations | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|